about
The role of complement in the pathogenesis of renal ischemia-reperfusion injury and fibrosisStructural and functional characterization of human and murine C5a anaphylatoxinsAttenuation of cGVHD by C5a/C5aR blockade is associated with increased frequency of TregThe complement system: history, pathways, cascade and inhibitors.Complement anaphylatoxins as immune regulators in cancer.1,25-Dihydroxyvitamin D3 promotes a sustained LPS-induced NF-κB-dependent expression of CD55 in human monocytic THP-1 cells.Novel potential interacting partners of fibronectin in spontaneous animal model of interstitial cystitisP-I snake venom metalloproteinase is able to activate the complement system by direct cleavage of central components of the cascadeComplement evasion by Bordetella pertussis: implications for improving current vaccinesComplement inhibition in a xenogeneic model of interactions between human whole blood and porcine endotheliumComplement 5a Enhances Hepatic Metastases of Colon Cancer via Monocyte Chemoattractant Protein-1-mediated Inflammatory Cell Infiltration.Endothelial cells elicit immune-enhancing responses to dengue virus infection.Evasion and interactions of the humoral innate immune response in pathogen invasion, autoimmune disease, and cancerAdipsin Is Associated with Multiple Sclerosis: A Follow-Up Study of Adipokines.Anticomplementary activity of horse IgG and F(ab')2 antivenoms.The complement C3a receptor is critical in defense against Chlamydia psittaci in mouse lung infection and required for antibody and optimal T cell response.Complement component 7 (C7), a potential tumor suppressor, is correlated with tumor progression and prognosis.Structural basis for the targeting of complement anaphylatoxin C5a using a mixed L-RNA/L-DNA aptamer.Transplantation and Damage-Associated Molecular Patterns (DAMPs).DAMP-Induced Allograft and Tumor Rejection: The Circle Is Closing.Old dogs-new tricks: immunoregulatory properties of C3 and C5 cleavage fragments.Complement factor H in host defense and immune evasion.Complementopathies.Rapid-onset clinical and mechanistic effects of anti-C5aR treatment in the mouse collagen-induced arthritis model.Treatment with anti-C5aR mAb leads to early-onset clinical and mechanistic effects in the murine delayed-type hypersensitivity arthritis model.Complement anaphylatoxin C4a inhibits C5a-induced neointima formation following arterial injury.C3a Enhances the Formation of Intestinal Organoids through C3aR1Complement inhibition attenuates acute kidney injury after ischemia-reperfusion and limits progression to renal fibrosis in mice.Inhibition of complement activation alleviates acute lung injury induced by highly pathogenic avian influenza H5N1 virus infection.No association between systemic complement activation and intensive care unit-acquired weakness.Quality of horse F(ab')2 antitoxins and anti-rabies immunoglobulins: protein content and anticomplementary activity.
P2860
Q26853263-FBB056FF-7721-4197-9AFE-1F068AE7A7C1Q27684270-06F5C90E-0085-402B-A0C3-FAB992FB6ACCQ33804224-D9B371F4-C0A1-485A-AB5B-1D58C17CBA0EQ34412336-114FC7B1-04D4-46A6-8C47-E67C86D96963Q34414162-C65BF0E8-CDDC-491B-BE72-997ED04D6984Q34477944-66164947-B53A-4186-85B3-4871FEFEF487Q34510967-33881710-E869-4C2A-9D9B-5E418EA54122Q35037062-1FCE43FF-06B7-4A2D-9603-2DACBE67A1D2Q35197120-81C63F6E-D212-40FC-8DBD-EDC5D18A7AD5Q35252177-9CAD30AC-E290-486E-9591-509F5FAE43AAQ35536219-B952E4C3-2BA7-432C-96FE-DA18E191799CQ36086727-D6399722-A005-4E84-8CE5-019C96175D6BQ36090335-FF582686-7AB2-436B-9848-4D14642071C5Q36304666-264CF774-D095-4C65-8CEB-1E858F7F7E81Q37623317-E485CAB3-82BF-48EC-B228-85D6DDB784CDQ37671928-0485C06F-80DB-49EF-AF17-8C42C5A51E42Q37699277-D9B62274-510C-45E4-A716-74F30BB34FB2Q38299564-F74225E7-6253-4905-9AF0-9F013DBFD2A2Q38898214-9D2A01AC-C63E-47F8-8B37-D9419AAF687DQ38928826-5EB296FE-6C5D-4004-9446-A2FF7854CB7EQ38991048-3387DC57-8082-442F-8091-04CBBEBF65ABQ39036058-46E388C4-DCBC-4664-B46A-9EC95C48FE9AQ39142842-AA6A34DA-8BB6-4CDE-9FA4-AD7D86482131Q40213039-212AA42A-6406-4402-B063-B6DFDE54EE84Q41010289-077D58C2-00A8-40F2-A8AB-92EBDF0FAC0EQ41087929-C97795E5-2CA7-4677-9609-70DF1D24D115Q41472557-CBD0D206-5FC1-406B-9D92-5D30775B7993Q41497854-50C6D679-3D79-4652-BA67-7E91109A846BQ45352011-C112436C-5E19-4A2D-BE46-98FB21E01D12Q55366266-9825FAE0-1664-4561-8E93-4C24B622EAEFQ55432779-5C0C59E0-D4B0-4FED-934F-7297C635C099
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The new face of anaphylatoxins in immune regulation.
@ast
The new face of anaphylatoxins in immune regulation.
@en
The new face of anaphylatoxins in immune regulation.
@nl
type
label
The new face of anaphylatoxins in immune regulation.
@ast
The new face of anaphylatoxins in immune regulation.
@en
The new face of anaphylatoxins in immune regulation.
@nl
prefLabel
The new face of anaphylatoxins in immune regulation.
@ast
The new face of anaphylatoxins in immune regulation.
@en
The new face of anaphylatoxins in immune regulation.
@nl
P1433
P1476
The new face of anaphylatoxins in immune regulation.
@en
P2093
Wuding Zhou
P304
P356
10.1016/J.IMBIO.2011.07.016
P577
2011-07-23T00:00:00Z